Shares of the distressed insulin maker Mannkind (MNKD) plummeted nearly 16% Thursday morning following a conference call with investors and analysts. Proposed changes to its Afrezza drug and its sales structure may not produce the results the drugmaker seeks.
More from Video
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.